Identifying biomarkers from adverse events to predict lung cancer outcomes
Development of adverse event (AE) derived biomarkers for predicting clinical outcomes in lung cancer
['FUNDING_R21'] · H. LEE MOFFITT CANCER CTR & RES INST · NIH-11010783
This study is looking at how side effects from lung cancer treatments, like high blood pressure and immune reactions, can help us understand how well patients are doing and find better ways to tailor their treatments for safety and effectiveness.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | H. LEE MOFFITT CANCER CTR & RES INST (nih funded) |
| Locations | 1 site (TAMPA, UNITED STATES) |
| Trial ID | NIH-11010783 on ClinicalTrials.gov |
What this research studies
This research focuses on developing biomarkers derived from adverse events (AEs) experienced by lung cancer patients during treatment. By analyzing various AEs, such as hypertension and immune-related reactions, the study aims to create a more comprehensive understanding of how these events correlate with patient survival outcomes. The approach involves utilizing advanced methodologies to assess the severity, frequency, and duration of AEs, transforming traditional data into actionable biomarkers that can guide personalized treatment strategies. This innovative analysis seeks to enhance patient safety and improve the efficacy of lung cancer therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are lung cancer patients undergoing chemotherapy who experience various adverse events during their treatment.
Not a fit: Patients with lung cancer who do not experience any adverse events during treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate predictions of clinical outcomes for lung cancer patients, ultimately improving treatment strategies and patient safety.
How similar studies have performed: Previous studies have shown promising results in utilizing adverse event data to predict clinical outcomes, indicating that this approach has potential for success.
Where this research is happening
TAMPA, UNITED STATES
- H. LEE MOFFITT CANCER CTR & RES INST — TAMPA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHEN, DUNG-TSA — H. LEE MOFFITT CANCER CTR & RES INST
- Study coordinator: CHEN, DUNG-TSA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: cancer clinical trial